- Home
- HSHP vs INBX Comparison
HSHP vs INBX Comparison
Compare HSHP & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HSHP
- INBX
- Stock Information
- Founded
- HSHP 2021
- INBX 2010
- Country
- HSHP Bermuda
- INBX United States
- Employees
- HSHP N/A
- INBX N/A
- Industry
- HSHP
- INBX Biotechnology: Pharmaceutical Preparations
- Sector
- HSHP
- INBX Health Care
- Exchange
- HSHP Nasdaq
- INBX Nasdaq
- Market Cap
- HSHP 231.4M
- INBX 190.2M
- IPO Year
- HSHP 2023
- INBX 2020
- Fundamental
- Price
- HSHP $5.34
- INBX $12.56
- Analyst Decision
- HSHP
- INBX Hold
- Analyst Count
- HSHP 0
- INBX 1
- Target Price
- HSHP N/A
- INBX N/A
- AVG Volume (30 Days)
- HSHP 168.3K
- INBX 88.8K
- Earning Date
- HSHP 02-20-2025
- INBX 11-14-2024
- Dividend Yield
- HSHP 8.98%
- INBX 6.77%
- EPS Growth
- HSHP 1125.21
- INBX N/A
- EPS
- HSHP 0.48
- INBX 119.38
- Revenue
- HSHP $123,580,000.00
- INBX $1,568,000.00
- Revenue This Year
- HSHP $252.71
- INBX N/A
- Revenue Next Year
- HSHP $11.04
- INBX N/A
- P/E Ratio
- HSHP $11.33
- INBX $0.11
- Revenue Growth
- HSHP 236.40
- INBX 19.24
- 52 Week Low
- HSHP $4.48
- INBX $10.80
- 52 Week High
- HSHP $9.76
- INBX $18.95
- Technical
- Relative Strength Index (RSI)
- HSHP 60.88
- INBX 42.38
- Support Level
- HSHP $4.74
- INBX $12.08
- Resistance Level
- HSHP $5.68
- INBX $13.60
- Average True Range (ATR)
- HSHP 0.17
- INBX 0.76
- MACD
- HSHP 0.09
- INBX 0.05
- Stochastic Oscillator
- HSHP 70.31
- INBX 20.87
About HSHP Himalaya Shipping Ltd.
Himalaya Shipping Ltd is an independent dry bulk company that focuses on owning and operating its Newcastlemax dry bulk carriers.
About INBX Inhibrx Inc.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.